Treatment-Related Complications and Functional Results after Ruthenium-106 Brachytherapy in Small to Medium Size Uveal Melanomas (Part 2)
Klinische Monatsblätter für Augenheilkunde · 01.02.2025 · 242 (02) · 116-126
DOI: 10.1055/a-2275-5575 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, erschienen am 01.02.2025. Verfasst von Fotios Lalos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Hospital of Essen, Germany. Hauptthemen laut MEDLINE: Brachytherapy, Melanoma, Uveal Neoplasms, Ruthenium Radioisotopes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Purpose
To analyze the treatment-related complications after ruthenium-106 brachytherapy in patients with uveal melanoma in terms of radiation-induced optic neuropathy, maculopathy and retinopathy, radiation-related vitreous hemorrhage, and retinal detachment, as well as secondary glaucoma and radiogenic cataract. In addition, the course of visual acuity was analyzed. Patients/Methods and Materials This retrospective study included 608 patients treated with ruthenium-106 brachytherapy between January 2008 and December 2010 at the Department of Ophthalmology, University Hospital Essen. The follow-up time was 11 years. The occurrence of the radiation-induced complications was analyzed using the Kaplan-Meier method. Cox regression was used for univariate and multivariate risk factor analyses. Hazard ratios were calculated for each variable.
Results
Regarding the complications, 34% (N = 207) of the patients had no reported side effects or complications during follow-up. Radiation optic neuropathy was observed in 18.8% (N = 114) of the patients, with a median time to onset of 16 months (range: 3 – 78 months). Radiation maculopathy occurred in 8.2% (N = 50) after a median time of 17 months (range: 3 – 67 months). Radiation retinopathy was observed in 20.1% (N = 122), with a median time to onset of 21 months (range: 6 – 67 months). Secondary glaucoma developed in 9.7% of the patients (N = 53) and radiogenic cataract in 46.8% (N = 227). Vitreous hemorrhage (11.8%, N = 72) and scleral necrosis (2.1%, N = 13) occurred relatively rarely.
Conclusion
The observed radiogenic complication rate is comparable with that reported in previous studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, University Hospital of Essen, Germany.
- Department of Radiotherapy, University Hospital of Essen, Germany.
- German Cancer Consortium (DKTK), Heidelberg, Partner Site University Hospital Essen, Germany.
Zitieren
APA
Lalos, F., Flühs, D., Guberina, M., Bornfeld, N., Stuschke, M., Sauerwein, W., & Bechrakis, N. E. (2025). Treatment-Related Complications and Functional Results after Ruthenium-106 Brachytherapy in Small to Medium Size Uveal Melanomas (Part 2). Klinische Monatsblätter für Augenheilkunde, 242(02), 116-126. https://doi.org/10.1055/a-2275-5575
Vancouver
Lalos F, Flühs D, Guberina M, Bornfeld N, Stuschke M, Sauerwein W, et al. Treatment-Related Complications and Functional Results after Ruthenium-106 Brachytherapy in Small to Medium Size Uveal Melanomas (Part 2). Klinische Monatsblätter für Augenheilkunde. 2025;242(02):116-126. doi:10.1055/a-2275-5575
BibTeX
@article{Lalos2025,
author = {Lalos, Fotios and Flühs, Dirk and Guberina, Maja and Bornfeld, Norbert and Stuschke, Martin and Sauerwein, Wolfgang and Bechrakis, Nikolaos E},
title = {Treatment-Related Complications and Functional Results after Ruthenium-106 Brachytherapy in Small to Medium Size Uveal Melanomas (Part 2)},
journal = {Klinische Monatsblätter für Augenheilkunde},
year = {2025},
volume = {242},
number = {02},
pages = {116--126},
doi = {10.1055/a-2275-5575}
}
EUVIMED